Warm AIHA that does not respond adequately to rituximab requires a defined escalation of therapy. In this setting, several distinct treatment categories are available, and the choice between them depends on the individual clinical picture.
This protocol applies to patients with warm autoimmune hemolytic anemia who have not achieved an adequate response to rituximab and require a structured next step in management.
When rituximab has not produced an adequate response, options include immunoglobulin administration, surgical intervention, and immunosuppressant-based regimens — the complete selection criteria, sequencing, and clinical considerations are set out in the full protocol.
DOI: 10.33590/emjhematol/GBUF7192